The results are in for the first-ever randomized clinical trial on UVC disinfection. The Benefits of Enhanced Terminal Room Disinfection (BETR-D) study was funded by the Centers for Disease Control and Prevention (CDC) and conducted across nine hospitals in the Duke Infection Control Outreach Network (DICON) from 2012-2014.
A new study proves that enhanced terminal room disinfection with Tru-D SmartUVC leads to a decrease in risk of acquisition of targeted multidrug-resistant organisms such as C. diff and VRE for all patients, hospital-wide. The study was recently published in The Lancet Infectious Diseases and discusses the prescribed secondary analysis of the BETR-D randomized clinical trial.
Leading researchers in infection prevention and control wanted to conduct a randomized clinical trial that would determine the efficacy, effectiveness and feasibility of enhanced terminal room disinfection to prevent hospital-acquired infections.
In addition to the BETR-D study, researchers have completed fifteen, independent, third-party studies on Tru-D that all demonstrate its effectiveness.
Several studies conducted contemporaneously with the BETR-D are expected to be published over time. The first such paper was recently published in Infection Control and Hospital Epidemiology and outlines the implementation process for Tru-D in the BETR-D study.
Two 5-foot-5 superbug-slaying machines have been deployed from the United States where they aid in the fight against the deadly Ebola virus outbreak at JFK Hospital and ELWA Hospital in Monrovia, Republic of Liberia.